Loading...
Loading...
MNMD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.8M |
| Gross Profit | -0.8M |
| Operating Expense | 20.9M |
| Operating I/L | -23.5M |
| Other Income/Expense | -4.0M |
| Interest Income | 1.3M |
| Pretax | -24.8M |
| Income Tax Expense | 2.7M |
| Net Income/Loss | -27.5M |
Mind Medicine (MindMed) Inc. is a clinical stage biopharmaceutical company specializing in the development of novel products for the treatment of brain health disorders related to psychiatry, addiction, pain, and neurology. The company's pipeline includes MM-120, currently in phase 2 for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain; MM-110, an a3ß4 nicotinic cholinergic receptor antagonist targeting opioid withdrawal; and MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder.
